Nothing is more personal than health care. And there’s no aspect of our lives where artificial intelligence stands to have a greater impact. Tools like generative AI have extraordinary potential for improving patient outcomes, accelerating drug discovery, and more.
At the same time, no topic better illustrates our discomfort with AI. The prospect of critical health decisions being made for us by algorithms is, for many people, a bridge too far. And AI presents other risks, too, including the possibility of biased outputs, false results, and new threats to patient privacy.
These are legitimate concerns. But we can’t afford to pass up the extraordinary benefits AI can offer. Deployed responsibly, AI systems can enable more accurate diagnostics, more personalized treatment, better care delivery, and greater wellness—all while bringing enormous cost savings for both health care providers and patients. Just as important, by expanding access to health care for underserved populations, AI can be a crucial tool for promoting greater health equity.
We’ve already seen the transformative potential of AI in pharmaceutical R&D. The astonishingly rapid development of life-saving vaccines against COVID-19 was fueled in part by robotic automation, AI algorithms, and machine-learning models, which allowed pharma companies to amplify and accelerate their development work.
The arrival of generative AI is further accelerating the discovery of new drugs and treatments. GenAI is improving clinical trial planning and execution processes and enabling more precision therapies—and in the process, it’s making medicine more accessible, affordable, and effective. Companies using generative AI are moving from novel target discovery to FDA drug approval in as little as 18 months while spending only a fraction of what the development and approval process typically costs.
The application of generative AI in the clinical stages will result in a further acceleration of time to market—and as drug development costs decrease, rare indications will become more economically viable. We’ll see other benefits as well. Generative AI will be able to analyze patient data to identify subgroups of patients that are likely to respond to specific treatments. It could also be used to identify how diseases might evolve to become drug resistant, enabling personalized therapies.
Meanwhile, generative AI is likely to transform the regulatory engagement process, both for sponsors and for regulators themselves. Faster development will increase the volume of drugs requiring approvals—and regulators will need employ their own GenAI tools in response.
AI is gaining significant traction in diagnosing illnesses. Visual AI agents already outperform radiologists at diagnosing some forms of cancer, and many startups and tech giants are working on generative AI-enabled oncology solutions to detect it even earlier.
In the future, generative AI could support real-time patient monitoring which, combined with data analysis to generate personalized insights, could lead to timely interventions before medical conditions worsen. It could also be used to encourage preventive care, wellness, and healthy behaviors via proactive personalized nudges through mobile apps, wearables, and monitoring devices—thus reducing the number of hospital visits.
In primary-care settings, AI can improve or replace some physician interactions—flagging issues or sending evidence-based recommendations and reminders prompted by a patient’s electronic health record, for instance. Pharmacies can deploy emotional AI to “listen” to conversations, detect emotional signals, and receive suggestions on how to provide better, more empathetic care to customers. And chatbots trained on GenAI models can deliver accessible and affordable mental health counseling.
Of course, given the emotional dimensions of health, patients will want to hear their diagnoses from human doctors. AI will not replace the human touch.
Several use cases of generative AI are in development across the health care industry:
Pharmaceutical Firms. Companies are using GenAI to develop mini proteins to treat rare cancers among traditionally underserved population groups. They’re using deep-learning AI and synthetic biology to design new therapeutic antibodies for cancer and immune diseases. And they’re developing machine-learning language models that can generate new protein sequences with specific functions—an innovative tool for new drug design to improve quality and access to affordable treatments.
Meanwhile, Nvidia‘s generative AI cloud service allows biopharma companies to access foundation models in genomics, chemistry, biology, and molecular dynamics. The service provides pretrained GenAI models, but it also enables researchers to fine-tune applications using their own proprietary data.
Medtechs. Generative AI could help companies create more personalized and patient-centered devices such as prosthetics and implants, equipping them with software that provides preventive maintenance and repairs. Generative AI-based platforms can also be used to predict and monitor brain aging, providing insights and tools to diagnose cognitive decline in patients with mental health and neurodegenerative disorders.
Other future applications could enable companies to further collect and analyze data via remote monitoring systems, leading to more effective patient interventions. Quality control applications could also predict when devices and equipment may need repairs, allowing caregivers to schedule maintenance and thus reduce downtime.
Payers and Providers. Payers are starting to leverage generative AI to improve risk management, cost reduction, and member engagement. Examples include automated underwriting and claims management processes and predictive models that identify and proactively manage high-risk segments based on a patient’s medical history, demographics, and social determinants of health—helping prevent and mitigate avoidable conditions and making care more equitable.
In addition to helping providers improve clinical outcomes, generative AI solutions can help maximize resource utilization for both clinical and administrative staff by automating processes such as documentation, claims handling, preauthorization or appeals letters, patient onboarding, and scheduling—thus enabling providers to devote more time to patients.
Public Health. Public health agencies, government ministries, and other health organizations could leverage generative AI to improve resource planning and allocation and to anticipate public health needs—by developing early warning systems for new COVID-19 variants, for example, that can proactively alert researchers, vaccine developers, health authorities, and policy makers.
AI technology could also be leveraged when reviewing the safety and efficacy of drugs, and public health groups could use it to predict disease outbreaks and mobilize resources to minimize impact.
To fulfill AI’s promise, providers and other health care organizations must ensure that generative AI is implemented safely. That means addressing the significant risks AI can pose, including:
The arrival of generative AI will undoubtedly lead to extraordinary medical advances. But in the end, health care will come down to what it always has: doctors and patients. Used responsibly, AI can be a powerful tool for both.
ABOUT BOSTON CONSULTING GROUP
Boston Consulting Group partners with leaders in business and society to tackle their most important challenges and capture their greatest opportunities. BCG was the pioneer in business strategy when it was founded in 1963. Today, we work closely with clients to embrace a transformational approach aimed at benefiting all stakeholders—empowering organizations to grow, build sustainable competitive advantage, and drive positive societal impact.
Our diverse, global teams bring deep industry and functional expertise and a range of perspectives that question the status quo and spark change. BCG delivers solutions through leading-edge management consulting, technology and design, and corporate and digital ventures. We work in a uniquely collaborative model across the firm and throughout all levels of the client organization, fueled by the goal of helping our clients thrive and enabling them to make the world a better place.
© Boston Consulting Group 2024. All rights reserved.
For information or permission to reprint, please contact BCG at email@example.com. To find the latest BCG content and register to receive e-alerts on this topic or others, please visit bcg.com. Follow Boston Consulting Group on Facebook and X (formerly Twitter).